ATU iHub client company Tympany Medical, in collaboration with Invermed Teoranta, the Royal College of Surgeons Ireland (RCSI), and The National College of Art & Design (NCAD), proudly announces a significant milestone in medical innovation with the endorsement of €6.8 million funding under Call 6 of the Disruptive Technologies Innovation Fund (DTIF). This funding marks a pivotal moment in the development of the Solascope, poised to become the world’s first sterile, sustainable, panoramic endoscope.

Minister for Enterprise, Trade and Employment, Simon Coveney, highlighted the transformative potential of the Solascope project, emphasizing its ability to revolutionise healthcare outcomes while promoting sustainability. “This collaborative endeavor embodies the spirit of innovation driving Ireland’s position as a leader in research and technology,” stated Minister Coveney.

Echoing Minister Coveney’s sentiment, Minister Simon Harris emphasized the critical synergy between research and industry, underscoring the broader societal benefits of such partnerships. “Projects like Solascope are emblematic of Ireland’s commitment to fostering innovation and cultivating a resilient, adaptive economy,” Minister Harris remarked.

Minister of State for Trade Promotion, Digital and Company Regulation, Dara Calleary, lauded the digital advancements embedded within the Solascope project, foreseeing transformative benefits for both healthcare practitioners and patients. “This initiative exemplifies Ireland’s dedication to digitalization, further bolstering our global competitiveness and economic growth,” Minister Calleary asserted.

Leo Clancy, CEO of Enterprise Ireland, commended Tympany Medical for its groundbreaking strides in medical technology. “The Solascope project exemplifies the spirit of Irish innovation, offering remarkable solutions to global challenges,” remarked Clancy.

The Solascope project, rooted in the principles of circular economy and sustainability, promises not only enhanced medical procedures but also a significant reduction in procedural time. This milestone funding from DTIF catapults Tympany Medical and its partners toward the commercial launch of Solascope, setting a new standard for medical device sustainability and efficacy.

Tympany Medical and its consortium members express their gratitude for the unwavering support from DTIF, underscoring the pivotal role of industry-academia collaboration in driving impactful innovation.

With this latest funding injection, Tympany Medical looks forward to realising its vision of transforming healthcare delivery through sustainable, cutting-edge technology.

About Tympany Medical: Tympany Medical is a pioneering medical technology company dedicated to revolutionising healthcare through innovative, sustainable solutions. With a commitment to excellence and sustainability, Tympany Medical is at the forefront of driving positive change in the medical industry. For more information, visit

Liz McGloughlin-CEO Tympany Medical, and Rory O’Callaghan, CTO Tympany Medical.